Overview

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.

Phase:

Phase 2

Details

Lead Sponsor:

R-Pharm

Collaborators:

Almedis
ChromSystemsLab
Scientific Center EFiS

Treatments:

Ritonavir
Sofosbuvir